Epilepsy

Drug-resistant epilepsy continues to affect roughly a third of patients despite an expanding pharmacopeia, prompting earlier escalation to surgical and neuromodulation approaches. GCNN 2027 will examine cenobamate’s seizure-freedom rates in focal epilepsy, ganaxolone for CDKL5 deficiency disorder, and the genetic-epilepsy pipeline targeting SCN1A (Dravet — STK-001 antisense), SCN2A, SCN8A and KCNQ2. Surgical content covers MRI-guided laser interstitial thermal therapy, robotic stereo-EEG, focused ultrasound for hypothalamic hamartoma, and the maturation of responsive neurostimulation (RNS) and deep brain stimulation of the anterior nucleus of the thalamus.